Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: A network analysis approach
Resumen: Psychopathological manifestations and cognitive impairments are core features of psychotic disorders. Polygenic risk scores (PRS) offer insights into the relationships between genetic vulnerability, symptomatology, and cognitive impairments. This study used a network analysis to explore the connections between PRS, cognition, psychopathology, and overall functional outcomes in individuals experiencing a first episode of psychosis (FEP). The study sample comprised 132 patients with FEP. Genetic data were used to construct PRS for mental disorders and cognitive traits via PRS-continuous shrinkage. We conducted comprehensive clinical and neuropsychological assessments at 2 months post-diagnosis and again at a 2-year follow-up. A network analysis was performed to generate two distinct networks and their centrality indices, encompassing 19 variables across domains such as symptoms, cognition, functioning, and PRS. Variables were grouped within related domains, and stronger relationships were observed within domains than between them. PRS for schizophrenia showed weak negative associations with attention, working memory, and verbal memory, while PRS for cognitive performance showed weak positive associations with attention. Negative symptoms were negatively associated with functioning and verbal memory at both the 2-month and 2-year assessments, as well as with social cognition at 2 years. Poor functioning was moderately related to greater severity of Positive and Negative Syndrome Scale dimensions. This study identified pathways linking PRS, cognition, symptoms, and functioning, suggesting that genetic risk may serve as a marker of vulnerability and disorder progression. The findings also highlight the importance of considering genetic predispositions alongside clinical and cognitive factors to better understand the heterogeneity of psychotic disorders.
Idioma: Inglés
DOI: 10.1016/j.euroneuro.2024.12.002
Año: 2025
Publicado en: EUROPEAN NEUROPSYCHOPHARMACOLOGY 92 (2025), 52-61
ISSN: 0924-977X

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CP21-00059
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-02148
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI19-00766
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI19-01698
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI20-00473
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI22-01985
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/RD16-0009-0025
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)

Derechos Reservados Derechos reservados por el editor de la revista


Exportado de SIDERAL (2025-01-22-14:46:14)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Psiquiatría



 Registro creado el 2025-01-22, última modificación el 2025-01-22


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)